

April 27, 2022

Guang Dong Kingfa Sci. & Tech.Co., Ltd. Xiaoge Yu Manager No. 28 Delong Ave., Shijiao Town, Qingcheng District Qingyuan, Guangdong 511545 China

Re: K213040

Trade/Device Name: Nitrile Patient Examination Gloves Blue Colored Tested For Use With

Chemotherapy Drugs, Nitrile Patient Examination Gloves Blue Violet Colored Tested For Use With Chemotherapy Drugs, Nitrile Patient Examination Gloves

Black Colored Tested For Use With Fentanyl Citrate

Regulation Number: 21 CFR 880.6250

Regulation Name: Non-Powdered Patient Examination Glove

Regulatory Class: Class I, reserved Product Code: LZA, LZC, OPJ, QDO

Dated: April 16, 2022 Received: April 18, 2022

Dear Xiaoge Yu:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

K213040 - Xiaoge Yu Page 2

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Bifeng Qian, M.D., Ph.D
Acting Assistant Director
DHT4B: Division of Infection Control
and Plastic Surgery Devices
OHT4: Office of Surgical
and Infection Control Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2023

See PRA Statement below.

510(k) Number (if known)
K213040

Device Name
Nitrile Patient Examination Gloves Blue Colored Tested For Use With Chemotherapy Drugs

Indications for Use (Describe)

The blue colored nitrile examination glove is intended to be worn on the hands of examiner's to prevent contamination between patient and examiner. This is a single-use, powder-free, non-sterile device.

The Nitrile Patient Examination Gloves Blue Colored were tested for use with chemotherapy drugs per ASTM D6978-05 (Reapproved 2019) Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs. The tested chemotherapy drug are as follows:

- Bleomycin Sulfate 15 mg/ml >240 min.
- Carboplatin 10 mg/ml >240 min.
- Carmustine (BCNU) 3.3 mg/ml 17.2 min.
- Cisplatin 1.0 mg/ml >240 min.
- Cyclophosphamide (Cytoxan) 20.0 mg/ml >240 min.
- Cytarabine HCI 100 mg/ml >240 min.
- Dacarbazine (DTIC)10.0 mg/ml >240 min.
- Daunorubicin 5.0 mg/ml >240 min.
- Docetaxel 10.0 mg/ml >240 min
- Doxorubicin HCI 2.0 mg/ml >240 min.
- Etoposide (Toposar) 20.0 mg/ml >240 min.
- Fluorouracil 50.0 mg/ml >240 min.
- Gemcitabine 38 mg/ml>240 min.
- Idarubicin 1 mg/ml >240 min.
- Ifosfamide 50.0 mg/ml >240 min.
- Irinotecan 20.0 mg/ml >240 min.
- Mechlorethamine HCI 1.0 mg/ml>240 min.
- Melphalan 5 mg/ml >240 min.
- Methotrexate 25 mg/ml >240 min.
- Mitromycin C. 0.5 mg/ml >240
- Mitoxantrone 2.0 mg/ml >240 min.
- Paclitaxel (Taxol) 6.0 mg/ml >240 min.
- Thiotepa 10.0 mg/ml 13.9 min.
- Vincristine Sulfate 1.0 mg/ml >240 min.

Warning: Do not use with Carmustine and Thiotepa.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2023 See PRA Statement below.

10(k) Number (if known)	
2213040	
evice Name	
litrile Patient Examination Gloves Blue Violet Colored Tested For Use With Chemotherapy Drugs	
adications for Use (Describe)	

The nitrile examination glove is intended to be worn on the hands of examiner's to prevent contamination between patient and examiner. This is a single-use, powder-free, non-sterile device.

The Nitrile Patient Examination Gloves Blue Violet Colored were tested for use with chemotherapy drugs per ASTM D6978-05 (Reapproved 2019) Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs.

The tested chemotherapy drug are as follows:

- Carmustine (BCNU) 3.3 mg/ml 65.3 min.
- Cisplatin 1.0 mg/ml >240 min.
- Cyclophosphamide (Cytoxan) 20.0 mg/ml >240 min.
- Dacarbazine (DTIC)10.0 mg/ml >240 min.
- Doxorubicin HCI 2.0 mg/ml >240 min.
- Etoposide (Toposar) 20.0 mg/ml >240 min.
- Fluorouracil 50.0 mg/ml >240 min.
- Methotrexate 25 mg/ml >240 min.
- Paclitaxel (Taxol) 6.0 mg/ml >240 min.
- Thiotepa 10.0 mg/ml 58.3 min.,

Warning: Do not use with Carmustine and Thiotepa.

CONTINUE ON A SEPARATE PAGE IF NEEDED.			
Prescription Use (Part 21 CFR 801 Subpart D)	Over-The-Counter Use (21 CFR 801 Subpart C)		
Type of Use (Select one or both, as applicable)			

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120

Expiration Date: 06/30/2023 See PRA Statement below.

510(k) Number (if known)	
K213040	
Device Name Nitrile Patient Examination Gloves Black Colored Tested For Use Wit	th Fentanyl Citrate
Indications for Use (Describe) The nitrile examination glove is intended to be worn on the hand and examiner. This is a single-use, powder-free, non-sterile dev	
The Nitrile Patient Examination Gloves Black Colored were tes (Reapproved 2019) Standard Practice for Assessment of Medica • Fentanyl Citrate 100mcg/2ml >240 minutes	
Type of Use (Select one or both, as applicable)	
Prescription Use (Part 21 CFR 801 Subpart D)	Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARA	TE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(k) summary: K213040

I. Submitter

GUANGDONG KINGFA SCI. & TECH.CO., LTD.

No.28 Delong Ave., Shijiao Town, Qingcheng District, Qingyuan, Guangdong, China

Contact person: Xiaoge Yu

Position: Manager

Tel.: +86-13570952157

E-mail: yuxiaoge@kingfa.com.cn

Preparation date: Apr. 27, 2022

US Agent

Jeff Zhang

Ucl-Reg Service Inc

602 Rockwood Rd Wilmington, DE US 19802

Phone: 516 2311209

Email: us-agent@glomed-info.com

II. Proposed Device

Device Trade Name Nitrile Patient Examination Gloves Blue Colored Tested For Use

With Chemotherapy Drugs

Nitrile Patient Examination Gloves Blue Violet Colored Tested

For Use With Chemotherapy Drugs

Nitrile Patient Examination Gloves Black Colored Tested For

Use With Fentanyl Citrate

Common name: Patient Examination Glove (Tested For Use With

Chemotherapy Drugs)

Regulation Number: 21 CFR 880.6250

Regulatory Class: Class I

Product code: LZA, LZC,OPJ, QDO Review Panel General Hospital

III. Predicate Devices

510(k) Number: K211220

Trade name: Nitrile Patient Examination Gloves Blue Tested For Use With

Chemotherapy Drugs

Nitrile Patient Examination Gloves Blue Violet Tested For Use

With Chemotherapy Drugs

Common name: Patient Examination Glove

Classification: Class I

Product Code: LZA, LZC,OPJ

IV. Device description

Power-Free Nitrile Examination Gloves (Tested for Use with Chemotherapy Drugs) are non-sterile, single use, disposable gloves intended for medical purposes to be worn on the hands of examiners to prevent contamination between a patient and an examiner. The gloves are offered in six sizes, x-small (6.5"), small (7"), medium (8"), large (8.5"), X-large (9"), XXL (9.5"). Three colors are available for all size, includes blue, blue violet and black.

The gloves are designed and manufactured in accordance with the ASTM D6319-19 standard and are tested for use with chemotherapy drugs per ASTM D6978-05 (Reapproved 2019).

V. Indication for use

A patient examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner.

These gloves were tested for use with chemotherapy drugs per ASTM D6978-05 (2019) Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs.

The Nitrile Patient Examination Gloves Blue Colored Tested Chemotherapy Drugs are as follows:

- Bleomycin Sulfate 15 mg/ml >240 min.
- Carboplatin 10 mg/ml >240 min.
- Carmustine (BCNU) 3.3 mg/ml 17.2 min.
- Cisplatin 1.0 mg/ml >240 min.
- Cyclophosphamide (Cytoxan) 20.0 mg/ml >240 min.
- Cytarabine HCl 100 mg/ml >240 min.
- Dacarbazine (DTIC)10.0 mg/ml >240 min.
- Daunorubicin 5.0 mg/ml >240 min.
- Docetaxel 10.0 mg/ml >240 min
- Doxorubicin HCl 2.0 mg/ml >240 min.
- Etoposide (Toposar) 20.0 mg/ml >240 min.

- Fluorouracil 50.0 mg/ml >240 min.
- Gemcitabine 38 mg/ml>240 min.
- Idarubicin 1 mg/ml >240 min.
- Ifosfamide 50.0 mg/ml >240 min.
- Irinotecan 20.0 mg/ml >240 min.
- Mechlorethamine HCl 1.0 mg/ml>240 min.
- Melphalan 5 mg/ml >240 min.
- Methotrexate 25 mg/ml >240 min.
- Mitromycin C. 0.5 mg/ml >240
- Mitoxantrone 2.0 mg/ml >240 min.
- Paclitaxel (Taxol) 6.0 mg/ml >240 min.
- Thiotepa 10.0 mg/ml 13.9 min.
- Vincristine Sulfate 1.0 mg/ml >240 min

Warning: Do not use with Carmustine and Thiotepa.

The Nitrile Patient Examination Gloves Blue Violet Colored Tested Chemotherapy Drugs as follows:

- Carmustine (BCNU) 3.3 mg/ml 65.3 min.
- Cisplatin 1.0 mg/ml >240 min.
- Cyclophosphamide (Cytoxan) 20.0 mg/ml >240 min.
- Dacarbazine (DTIC)10.0 mg/ml >240 min.
- Doxorubicin HCl 2.0 mg/ml >240 min.
- Etoposide (Toposar) 20.0 mg/ml >240 min.
- Fluorouracil 50.0 mg/ml >240 min.
- Methotrexate 25 mg/ml >240 min.
- Paclitaxel (Taxol) 6.0 mg/ml >240 min.
- Thiotepa 10.0 mg/ml 58.3 min.

Warning: Do not use with Carmustine and Thiotepa.

The Nitrile Patient Examination Gloves Black Colored Tested with Fentanyl Citrate

Fentanyl Citrate 100mcg/2ml >240 minutes

VI. Comparison of technological characteristics with the predicate devices

Table 1 Comparison of Natural Rubber Surgical Gloves

Item	Proposed device	Predicate device	Discussion
	(K213040)	(K211220)	

Product name	Nitrile Patient Examination Gloves Blue Colored Tested For Use With Chemotherapy Drugs. Nitrile Patient Examination Gloves Blue Violet Colored Tested For Use With Chemotherapy Drugs. Nitrile Patient Examination Gloves Black Colored Tested For Use With Fentanyl Citrate	Nitrile Patient Examination Gloves Blue Tested For Use With Chemotherapy Drugs Nitrile Patient Examination Gloves Blue Violet Tested For Use With Chemotherapy Drugs	-
Product Code	LZA, LZC,OPJ, QDO	LZA, LZC,OPJ	Similar
Regulation No.	21 CFR 880.6250	21 CFR 880.6250	Same
Classification	Class I	Class I	Same
Powder free	Yes	Yes	Same
Indication for use	The nitrile examination glove is intended to be worn on the hands of examiner's to prevent contamination between patient and examiner. This is a single-use, powder-free, non-sterile device. These gloves were tested for use with chemotherapy drugs per ASTM D6978-05 (Reapproved 2019) Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs.	A patient examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner. These gloves were tested for use with chemotherapy drugs as per ASTM D6978-05 (Reapproved 2019) Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs	Similar
Main Material	Powder-Free Nitrile	Powder-Free Nitrile	Same

Color	Blue, Blue violet, Black	Blue, Blue violet	Similar ²
Size	x-small, small, medium,	small, medium, large,	Similar
	large, x-large, XX-large	x-large	
Dimensions –	Complies with ASTM	Complies with ASTM	Same
Length	D6319-19	D6319-19	
	XS (220mm min)		
	S (220mm min)	S (220mm min)	
	M (230mm min)	M (230mm min)	
	L (230mm min)	L (230mm min)	
	XL (230mm min)	XL (230mm min)	
	XXL (230mm min)		
Dimensions –	Complies with ASTM	Complies with ASTM	Similar
Width	D6319-19)	D6319-19	
	XS (70±10mm)		
	S (80±10mm)	S (80±10mm)	
	M (95±10mm)	M (95±10mm)	
	L (110±10mm)	L (110±10mm)	
	XL (120±10mm)	XL (120±10mm)	
	XXL (≥120mm)		
Dimensions –	Complies with:	Complies with:	Same
Thickness	ASTM D6319-19	ASTM D6319-19	
	Palm: 0.05mm min	Palm: 0.05mm min	
	Finger: 0.11mm min	Finger: 0.11mm min	
Physical	Complies with:	Complies with:	Same
Properties	ASTM D6319-19	ASTM D6319-19	
	minimum:	minimum:	
	Tensile Strength:	Tensile Strength:	
	Before Aging ≥14 MPa,	Before Aging ≥14 MPa,	
	min.	min.	
	After Aging ≥ 14 MPa,	After Aging ≥ 14 MPa,	
	min.	min.	
	Elongation:	Elongation:	Same
	Before Aging 500%, min.	Before Aging 500%, min.	
	After Aging 400%, min.	After Aging 400%, min.	
Freedom from	Complies with ASTM	Complies with ASTM	Same
Holes	D6319-19 and ASTM	D6319-19 and ASTM	
	D5151-19 G-1, AQL 1.5	D5151-19 G-1, AQL 1.5	
Residual	Complies with:	Complies with:	Same
Powder	ASTM D6319-19	ASTM D6319-19	

	<2mg per glove	<2mg per glove	
Contact	Limited <24 hours	Limited <24 hours	Same
Durations			
Biocompatibility	ISO 10993-10:	ISO 10993-10:	Same
	Not a skin irritant	Not a skin irritant	
	Not a skin sensitizer	Not a skin sensitizer	
	At the neat extraction,	At the neat extraction, the	
	the test article is	test article is considered	
	considered cytotoxic, but	cytotoxic, but the acute	
	the acute systemic	systemic toxicity results	
	toxicity results	demonstrate the device	
	demonstrate the device	will not cause a systemic	
	will not cause a systemic	effect.	
	effect.		
Sterility	Non-sterile	Non-sterile	Same
Rx Only or OTC	Over the Counter	Over the Counter	Same
Chemotherapy	Nitrile Patient	Nitrile Patient	/
Drugs	Examination Gloves	Examination Gloves Blue	
	Blue Colored Tested For	Tested For Use With	
	Use With Chemotherapy	Chemotherapy Drugs	
	Drugs		
	Bleomycin Sulfate 15 mg/ml >240 min.	NA	Similar ¹
	Carboplatin 10	NA	
	mg/ml >240 min.		
	Carmustine (BCNU) 3.3	Carmustine (BCNU) 3.3	
	mg/ml 17.2 min.	mg/ml 65.3 min.	
	Cisplatin 1.0 mg/ml >240	Cisplatin 1.0 mg/ml >240	
	min.	min.	
	Cyclophosphamide	Cyclophosphamide	
	(Cytoxan) 20.0	(Cytoxan) 20.0	
	mg/ml >240 min.	mg/ml >240 min.	
	Cytarabine HCI 100	NA	
	mg/ml >240 min.		
	Dacarbazine (DTIC)10.0	Dacarbazine (DTIC)10.0	
	mg/ml >240 min.	mg/ml >240 min.	
	Daunorubicin 5.0	NA	
	mg/ml >240 min.		
	Docetaxel 10.0 mg/ml	NA	

>240 min		
Doxorubicin HCl 2.0	Doxorubicin	
mg/ml >240 min.	Hydrochloride 2.0	
	mg/ml >240 min.	
Etoposide (Toposar)	Etoposide (Toposar) 20.0	
20.0 mg/ml >240 min.	mg/ml >240 min.	
Fluorouracil 50.0	Fluorouracil 50.0	
mg/ml >240 min.	mg/ml >240 min.	
Gemcitabine 38	NA	
mg/ml>240 min.		
Idarubicin 1 mg/ml >240	NA	
min.		
Ifosfamide 50.0	NA	
mg/ml >240 min.		
Irinotecan 20.0 mg/ml	NA	
>240 min.		
Mechlorethamine HCI	NA	
1.0 mg/ml>240 min.		
Melphalan 5 mg/ml >240	NA	
min.		
Methotrexate 25	NA	
mg/ml >240 min.		
Mitromycin C. 0.5	NA	
mg/ml >240		
Mitoxantrone 2.0 mg/ml	NA	
>240 min.		
Paclitaxel (Taxol) 6.0	Paclitaxel (Taxol) 6.0	
mg/ml >240 min.	mg/ml >240 min.	
Thiotepa 10.0 mg/ml	Thiotepa 10.0 mg/ml	
13.9 min.	58.3min.	
Vincristine Sulfate 1.0	NA	
mg/ml >240 min.		
Nitrile Patient	Nitrile Patient	/
Examination Gloves	Examination Gloves Blue	
Blue Violet Colored	Violet Tested For Use	
Tested For Use With	With Chemotherapy	
Chemotherapy Drugs	Drugs	4
Carmustine (BCNU) 3.3	Carmustine (BCNU) 3.3	Similar ¹
mg/ml 65.3 min.	mg/ml 65.3 min.	

Ci	isplatin 1.0 mg/n	nl >240	Cisplatin 1.0 mg/ml	>240	
m	nin.		min.		
C	yclophosphamic	le	Cyclophosphamide		
(C	Cytoxan)	20.0	(Cytoxan)	20.0	
m	ng/ml >240 min.		mg/ml >240 min.		
Da	acarbazine (DT	IC)10.0	Dacarbazine (DTIC)10.0	
m	ng/ml >240 min.		mg/ml >240 min.		
Do	oxorubicin		Doxorubicin		
Hy	ydrochloride	2.0	Hydrochloride	2.0	
m	ng/ml >240 min.		mg/ml >240 min.		
Et	toposide (To	oposar)	Etoposide (Toposar)	20.0	
20	0.0 mg/ml >240	min.	mg/ml >240 min.		
FI	luorouracil	50.0	Fluorouracil	50.0	
m	ng/ml >240 min.		mg/ml >240 min.		
M	lethotrexate	25	NA		
m	ng/ml >240 min.				
Do	oxorubicin		Doxorubicin		
H	ydrochloride	2.0	Hydrochloride	2.0	
m	ng/ml >240 min.		mg/ml >240 min.		
Et	toposide (To	oposar)	Etoposide (Toposar)	20.0	
20	0.0 mg/ml >240	min.	mg/ml >240 min.		
Ni	itrile	Patient	1		New add
		Gloves			black color
	lack Colored	Tested			glove ²
Wi	ith Fentanyl Citra	ate			
•	Fentanyl	Citrate	NA		
	00mcg/2ml	>240			
m	ninutes				

¹ Add new 15 kinds of the chemotherapy label claim to the blue colored glove and add one chemotherapy drug test to the blue violet colored glove, which the both of glove has got the clearance under K211220. The permeation testing was conducted per ASTM D6978-05 (Reapproved 2019) to support the addition of the labeling claim.

² Add a new model glove with black and label claim the device tested by Fentanyl Citrate. Only change the colorant additives during manufacturing. The biocompatibility testing has been conduct on the black gloves and the test results prove the black glove is biologically safe as the previous device. In addition, the physical performances of the proposed device were performed on the final device per ASTM D6319-19.

VII. Non-Clinical Testing

Non clinical tests were conducted in accordance with following standards to verify that the proposed device met all design specifications.

Items	Methodology /	Acceptance Criteria	Results
	Standard		
Palm width	ASTM D3767-03(2020)	XS (70±10mm)	Pass
		S (80±10mm)	
		M (95±10mm)	
		L (110±10mm)	
		XL (120±10mm)	
		XXL (≧120mm)	
Length	ASTM D3767-03(2020)	XS (220mm min)	Pass
		S (220mm min)	
		M (230mm min)	
		L (230mm min)	
		XL (230mm min)	
		XXL (230mm min)	
Thickness	ASTM D3767-03(2020)	Finger: 0.11mm	Pass
		Palm: 0.05mm	
Freedom	ASTM D5151-19	Freedom free hole	Pass
from holes		AQL 2.5	
Physical Propert	l ies (before aging)		
Tensile	ASTM D412-16	≥14Mpa	Pass
Strength		-	
Ultimate	ASTM D412-16	≥500%	Pass
Elongation			
Physical Propert	ies (after aging)		
Tensile	ASTM D573-04(2019)	≥14Mpa	
Strength			
Ultimate	ASTM D573-04(2019)	≥400%	Pass
Elongation			
Residual	ASTM D6124-06(2017)	≤2mg per glove	Pass
Powder			
Content			
Cytotoxic	ISO 10993-5	Non-cytotoxic	Under
			conditions of the
			study, device

			extract is
			cytotoxic.
Acute Systemic	ISO 10993-11	Non-acute systemic Under	
Toxicity		toxicity	conditions of`
			the study, did
			not show acute
			systemic toxicity
			in vivo / Pass
Irritation	ISO 10993-10	Non-irritating	Under the
			conditions of the
			study, not an
			irritant/ Pass
Sensitization	ISO 10993-10	Non-sensitizing	Under
			conditions of the
			study, not a
			sensitizer./ Pass

VIII. Clinical Testing

No clinical study is included in this submission.

IX. Conclusion

The conclusions drawn from the nonclinical tests demonstrate that the subject device Power-Free Nitrile Examination Gloves (Tested for Use with Chemotherapy Drugs) is as safe, as effective, and performs as well as or better than the legally marketed predicated device in K211220.